Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Acquires $1,838,834.12 in Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd purchased 236,354 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were purchased at an average cost of $7.78 per share, with a total value of $1,838,834.12. Following the completion of the purchase, the insider owned 12,129,925 shares in the company, valued at $94,370,816.50. This represents a 1.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Tuesday, October 6th, L1 Capital Pty Ltd acquired 272,695 shares of Anteris Technologies Global stock. The stock was purchased at an average cost of $7.18 per share, for a total transaction of $1,957,950.10.
• On Monday, October 5th, L1 Capital Pty Ltd acquired 648,455 shares of Anteris Technologies Global stock. The stock was purchased at an average price of $7.51 per share, with a total value of $4,869,897.05.
• On Thursday, October 1st, L1 Capital Pty Ltd bought 322,940 shares of Anteris Technologies Global stock. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $2,454,344.00.
• On Wednesday, September 30th, L1 Capital Pty Ltd purchased 74,286 shares of Anteris Technologies Global stock. The stock was acquired at an average price of $7.72 per share, for a total transaction of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total transaction of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total transaction of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total transaction of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total transaction of $120,001.63.

Anteris Technologies Global Stock Performance

NASDAQ AVR opened at $6.63 on Friday. Anteris Technologies Global Corp. has a 1 year low of $3.30 and a 1 year high of $11.06. The business’s fifty day moving average is $8.41 and its two-hundred day moving average is $8.03. The stock has a market capitalization of $646.16 million, a P/E ratio of -3.40 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The company had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.During the same period in the prior year, the business earned ($0.58) earnings per share. On average, research analysts forecast that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AVR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Friday, August 14th. Barclays raised shares of Anteris Technologies Global to a “hold” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Anteris Technologies Global presently has an average rating of “Hold” and an average price target of $14.00.

Key Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder continued buying. L1 Capital purchased 272,695 AVR shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48%. This follows several additional purchases in late September and early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
• Neutral Sentiment: Barclays initiated coverage with a Hold-equivalent view. Barclays’ reported “Hold” or “Equal Weight” stance suggests the firm sees limited near-term evidence for a stronger bullish recommendation. The coverage provides additional visibility but is unlikely to be a major catalyst by itself. Barclays AVR rating report
• Neutral Sentiment: Share and incentive-plan records were updated. Anteris reported changes involving CHESS Depositary Interests and employee equity incentives. These administrative updates do not provide a new clinical or commercial catalyst, though investors will monitor their effect on the share count. Anteris CDI and equity incentive update
• Negative Sentiment: Expanded unquoted equity may raise dilution concerns. The employee incentive-plan announcement adds to investor attention on potential future share issuance. For a clinical-stage company that is not yet profitable, the prospect of additional equity compensation or dilution can weigh on sentiment. Anteris employee incentive-plan announcement

Institutional Trading of Anteris Technologies Global

Several large investors have recently added to or reduced their stakes in AVR. Abel Hall LLC purchased a new stake in shares of Anteris Technologies Global in the first quarter valued at $63,000. J. Derek Lewis & Associates Inc. purchased a new position in shares of Anteris Technologies Global during the fourth quarter valued at $70,000. Legal & General Group Plc purchased a new position in shares of Anteris Technologies Global during the second quarter valued at $78,000. Bartlett & CO. Wealth Management LLC raised its position in Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after buying an additional 8,200 shares during the period. Finally, Cetera Investment Advisers raised its position in Anteris Technologies Global by 64.7% during the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after buying an additional 6,500 shares during the period.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.